Antibacterial-coated Sutures at Time of Cesarean
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease, Hospital |
| Therapuetic Areas: | Immunology / Infectious Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 1/23/2019 |
| Start Date: | January 9, 2018 |
| End Date: | January 2021 |
| Contact: | Violetta Lozovyy, M.D. |
| Email: | vilozovy@utmb.edu |
| Phone: | 409-772-1571 |
Abdominal closure with antibacterial-coated sutures has been shown to reduce wound infections
after a number of surgical procedures, but none of the previous trials included cesarean
delivery. Our objective is to determine whether use of antibacterial-coated sutures reduces
surgical site infection (SSI) after cesarean delivery.
after a number of surgical procedures, but none of the previous trials included cesarean
delivery. Our objective is to determine whether use of antibacterial-coated sutures reduces
surgical site infection (SSI) after cesarean delivery.
A review of 18 studies demonstrated a significant benefit of antimicrobial coated sutures in
reducing SSI (RCTs: OR 0.72; 95% CI 0.59-0.88; observational studies: OR 0.58; 95% CI
0.40-0.83). As there are no clinical trials focusing on cesarean delivery, and because the
risk factors and pathogenesis for post-cesarean SSI may not mirror other procedures, further
data is needed before generalizing the WHO recommendations to cesarean procedures.
reducing SSI (RCTs: OR 0.72; 95% CI 0.59-0.88; observational studies: OR 0.58; 95% CI
0.40-0.83). As there are no clinical trials focusing on cesarean delivery, and because the
risk factors and pathogenesis for post-cesarean SSI may not mirror other procedures, further
data is needed before generalizing the WHO recommendations to cesarean procedures.
Inclusion Criteria:
- 18-50 years of age.
- Women ≥ 24 weeks' viable gestation.
- To undergo cesarean delivery.
Exclusion Criteria:
- Patient unwilling or unable to provide consent.
- No prenatal care or a non-resident patient who is unlikely to be followed-up after
delivery.
- Immunosuppressed patients: i.e., taking systemic immunosuppressant or steroids (e.g.
transplant patients; not including steroids for lung maturity), HIV with CD4<200, or
other.
- Decision to use other than suture closure (e.g. secondary wound closure, mesh
closure).
- Skin infection.
- Coagulopathy.
- High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled
hysterectomy, bowel or adnexal surgery).
- Allergy to Triclosan.
- Incarcerated individuals.
We found this trial at
1
site
Click here to add this to my saved trials
